pISSN 1226-6051
eISSN 2508-786X

Fig. 2.

Download original image
Fig. 2. Survival analysis A) progression-free survival (PFS) for patients treated with nivolumab or pembrolizumab; grey area represents 95% confident intervals, B) PFS by medication type (nivolumab vs pembrolizumab), C) PFS by cancer type (non-small cell lung cancer vs other cancers), D) PFS by Programmed death-ligand 1 expression (≥50% vs <50%).
Korean J Clin Pharm 2020;30:11-8 https://doi.org/10.24304/kjcp.2020.30.1.11
© 2020 Korean J Clin Pharm